Contact this trialFirst, we need to learn more about you.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Acalabrutinib + Lenalidomide + Rituximab for Mantle Cell Lymphoma
Recruiting1 awardPhase 2
New York, New York
This trial is testing a new combination therapy for mantle cell lymphoma, which is a cancer of the lymph nodes. The treatment consists of 12 cycles of three drugs, after which responding patients can enter a maintenance phase. The goal is to see if the treatment is effective and safe.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.